A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG | NCT07781436 | Trialant

Not yet recruitingInterventionalNot ApplicableUpdated Aug 24, 2026

A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG

Randomized Controlled Trial of Fuzheng Yangxin Formula in Enhanced Recovery After Coronary Artery Bypass Grafting

Overview

Key facts that identify this study and show where it stands today.

What the study is about and why it is being run, in the researchers' own words.

Official Title: Randomized Controlled Trial of Fuzheng Yangxin Formula in Enhanced Recovery After Coronary Artery Bypass Grafting
Brief Summary: This study aims to evaluate the efficacy and safety of Fuzheng Yangxin Formula (FZYXF) in the treatment of qi-yin deficiency syndrome after coronary artery bypass grafting (CABG), formulate an integrated Chinese and Western medicine rehabilitation protocol, develop special proprietary Chinese medicines for postoperative patients, establish a postoperative rehabilitation database, and promote the standardized application and achievement transformation of integrated Chinese and Western medicine therapy in cardiac surgery.
Detailed Description: This study adopts a randomized controlled trial design. A total of 230 patients presenting with qi-yin deficiency syndrome after coronary artery bypass grafting (CABG) will be enrolled and randomly assigned to the Fuzheng Yangxin Formula (FZYXF) experimental group (115 patients) and the control group (115 patients). The primary outcome is the Seattle Angina Questionnaire (SAQ) score at 7 days after medication. Secondary outcomes include perioperative safety and follow-up health assessments to comprehensively evaluate the therapeutic efficacy and safety.

The medical conditions and diseases this study investigates.

The treatments and procedures being evaluated in this study.

Who can join this study and the criteria used to decide.

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Eligibility Criteria: Inclusion Criteria:

-Patients who have undergone coronary artery bypass grafting (CABG) and present with postoperative qi-yin deficiency syndrome.

Exclusion Criteria:

Patients with hypersensitivity to any components of Fuzheng Yangxin Formula granules.

Patients with fever or common cold after surgery.

Patients with severe postoperative liver and kidney dysfunction.

Patients who receive concurrent valve surgery or other intracardiac operations

Patients with end-stage malignant tumors

Patients with uncontrolled infection or bleeding

Patients with progressive degenerative systemic diseases, such as severe trauma, multiple organ failure and other severe impairment of vital organ function including severely damaged liver function

Patients with severe heart failure or cardiogenic shock who cannot tolerate treatment.

How the study is designed and how its participant groups are organized.

The people to reach with questions about this study or how to join it.

Gong Yichen, DoctorContact

18611693463@126.com+8618611693463

Where the study is run and whether each site is currently recruiting.

Peking University 3rd hospital

Beijing, China

The organizations and people involved in this study.

Other registered studies that closely resemble this one.